Form 4: Beam Therapeutics CEO Executes Planned Stock Sales, Receives RSU Grant

Beam Therapeutics CEO John M. Evans executed pre-scheduled stock option exercises and sales, while also receiving a new restricted stock unit grant.

Summary

• John M. Evans, CEO and Director of Beam Therapeutics Inc. (BEAM), reported multiple transactions involving the company's common stock.
• On March 30, 2026, Mr. Evans acquired 25,000 shares of common stock by exercising stock options at a price of $0.67 per share.
• Concurrently on March 30, 2026, he disposed of 25,000 shares of common stock at a weighted average price of $22.3692 per share, ranging from $22.03 to $22.70.
• On March 31, 2026, Mr. Evans again acquired 25,000 shares of common stock by exercising stock options at $0.67 per share.
• Also on March 31, 2026, he disposed of another 25,000 shares of common stock at a weighted average price of $22.7634 per share, ranging from $22.34 to $23.21.
• These option exercises and sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Evans on May 16, 2025.
• On March 31, 2026, Mr. Evans was granted 90,000 restricted stock units (RSUs) under the BEAM 2019 Equity Incentive Plan, with a grant price of $0.00.
• The RSUs will vest in four substantially equal annual installments starting from the grant date, contingent on Mr. Evans' continued service.
• Following these transactions, Mr. Evans directly beneficially owns 1,076,667 shares of common stock and indirectly owns 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust.
• He also holds 18,672 stock options (right to buy) with an exercise price of $0.67, expiring on May 8, 2028.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While there are sales, they are pre-planned under a 10b5-1 plan, and the significant RSU grant and achievement of a performance milestone for prior options signal continued confidence and long-term alignment.

Positives

• The grant of 90,000 restricted stock units (RSUs) demonstrates continued equity incentive for the CEO, aligning his interests with long-term shareholder value.
• A performance condition for a previously granted stock option (May 8, 2018) was achieved on April 3, 2024, resulting in the vesting of 99,336 shares, indicating progress on development milestones related to base editing applications.

Negatives

• The disposition of 50,000 shares of common stock by the CEO, even if pre-planned, represents a reduction in his direct ownership.

Future Outlook

The newly granted 90,000 restricted stock units are scheduled to vest in four substantially equal annual installments, contingent on the CEO's continued service, indicating a long-term incentive structure.

Management Comments

• The reporting person adopted a Rule 10b5-1 trading plan on May 16, 2025, under which these transactions were executed.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under a Rule 10b5-1 plan, are common for executives to manage personal liquidity and diversification while adhering to insider trading regulations. The combination of option exercises, sales, and new RSU grants reflects a typical compensation and personal financial management strategy for a CEO in the biotechnology sector.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices for corporate executives to pre-arrange stock transactions, providing an affirmative defense against insider trading allegations. This is a standard mechanism across publicly traded companies, including those in the biotech industry like Moderna or CRISPR Therapeutics, where executives often hold significant equity.
• The grant of restricted stock units (RSUs) as part of executive compensation is a common incentive structure, similar to those seen at peer companies, designed to align management's long-term interests with shareholder value creation.

Stakeholder Impact

• Shareholders observe the CEO's equity transactions, which, despite being pre-planned, provide insight into management's personal financial strategy and long-term commitment to the company through RSU vesting.

Next Steps

• The 90,000 restricted stock units granted on March 31, 2026, will vest in four substantially equal annual installments, subject to the CEO's continued service.

Key Dates

Recommendation

The transactions are largely neutral for investors. The sales were pre-planned under a 10b5-1 plan, indicating a structured approach to liquidity rather than a sudden loss of confidence. This is balanced by a substantial RSU grant, which aligns the CEO's long-term incentives with the company's performance. Therefore, a 'hold' recommendation is appropriate as these events do not fundamentally alter the investment thesis.

Keywords

Beam Therapeutics, BEAM, Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSU, Equity Incentive Plan, John M. Evans, CEO, 10b5-1 Plan